This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.
At the conclusion of this course, participants will be able to:
. Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
. Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice
. Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
. Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT

Prices:
Practicing Physician/Industry: USD 1495.00,
Military/Retired/Scientist/VA: USD 1295.00,
PA/Nurse: USD 1195.00,
Resident/Fellow: USD 1095.00,
Technologist: USD 995.00

Speakers: Phillip Kuo, MD, PhD, FACR, Andrew Quon, MD, Don C. Yoo, MD

Category: Conferences | Science, Health and Medicine | CME (Continuing Medical Education)

Date and Time: 16th October 2025 at 7:30 am to 17th October 2025 at 4:45 pm

Venue details: Encore At Wynn Las Vegas, 3121 S Las Vegas Blvd, Las Vegas, NV, 89109, United States